Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients

David Price, Ashish Sharma, Frank Cerasoli

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive disease with increasing incidence and mortality. Tiotropium is an inhaled long-acting anti-cholinergic for the maintenance treatment of COPD. OBJECTIVE: To review biochemical and pharmacokinetic data on tiotropium and discuss in the context of tiotropium's efficacy and safety in COPD. METHODS: Review of previously done pharmacokinetic studies performed by the manufacturer of tiotropium. Data obtained through peer-reviewed publications and regulatory websites. RESULTS/CONCLUSIONS: The long duration of action with tiotropium is owing to prolonged, competitive binding to M(3) muscarinic receptors. Tiotropium is poorly absorbed following inhalation, which largely limits side effects. Metabolism of absorbed drug is minimal and excretion is largely through the kidneys. Tiotropium is efficacious and well tolerated by patients with COPD.
Original languageEnglish
Pages (from-to)417-424
Number of pages8
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume5
Issue number4
DOIs
Publication statusPublished - 1 Apr 2009

Fingerprint

Pulmonary diseases
Pharmacokinetics
Chronic Obstructive Pulmonary Disease
Pharmacology
Competitive Binding
Cholinergic Antagonists
Muscarinic Receptors
Tiotropium Bromide
Metabolism
Inhalation
Publications
Websites
Kidney
Safety
Mortality
Incidence
Pharmaceutical Preparations

Keywords

  • administration, inhalation
  • animals
  • bronchodilator agents
  • humans
  • protein binding
  • pulmonary disease, chronic obstructive
  • receptors, muscarinic
  • scopolamine derivatives

Cite this

Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients. / Price, David; Sharma, Ashish; Cerasoli, Frank.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 5, No. 4, 01.04.2009, p. 417-424.

Research output: Contribution to journalArticle

@article{0fd533bc3444499abef3103940102bdd,
title = "Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients",
abstract = "BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive disease with increasing incidence and mortality. Tiotropium is an inhaled long-acting anti-cholinergic for the maintenance treatment of COPD. OBJECTIVE: To review biochemical and pharmacokinetic data on tiotropium and discuss in the context of tiotropium's efficacy and safety in COPD. METHODS: Review of previously done pharmacokinetic studies performed by the manufacturer of tiotropium. Data obtained through peer-reviewed publications and regulatory websites. RESULTS/CONCLUSIONS: The long duration of action with tiotropium is owing to prolonged, competitive binding to M(3) muscarinic receptors. Tiotropium is poorly absorbed following inhalation, which largely limits side effects. Metabolism of absorbed drug is minimal and excretion is largely through the kidneys. Tiotropium is efficacious and well tolerated by patients with COPD.",
keywords = "administration, inhalation, animals, bronchodilator agents, humans, protein binding, pulmonary disease, chronic obstructive, receptors, muscarinic, scopolamine derivatives",
author = "David Price and Ashish Sharma and Frank Cerasoli",
year = "2009",
month = "4",
day = "1",
doi = "10.1517/17425250902828337",
language = "English",
volume = "5",
pages = "417--424",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Informa Healthcare",
number = "4",

}

TY - JOUR

T1 - Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients

AU - Price, David

AU - Sharma, Ashish

AU - Cerasoli, Frank

PY - 2009/4/1

Y1 - 2009/4/1

N2 - BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive disease with increasing incidence and mortality. Tiotropium is an inhaled long-acting anti-cholinergic for the maintenance treatment of COPD. OBJECTIVE: To review biochemical and pharmacokinetic data on tiotropium and discuss in the context of tiotropium's efficacy and safety in COPD. METHODS: Review of previously done pharmacokinetic studies performed by the manufacturer of tiotropium. Data obtained through peer-reviewed publications and regulatory websites. RESULTS/CONCLUSIONS: The long duration of action with tiotropium is owing to prolonged, competitive binding to M(3) muscarinic receptors. Tiotropium is poorly absorbed following inhalation, which largely limits side effects. Metabolism of absorbed drug is minimal and excretion is largely through the kidneys. Tiotropium is efficacious and well tolerated by patients with COPD.

AB - BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a progressive disease with increasing incidence and mortality. Tiotropium is an inhaled long-acting anti-cholinergic for the maintenance treatment of COPD. OBJECTIVE: To review biochemical and pharmacokinetic data on tiotropium and discuss in the context of tiotropium's efficacy and safety in COPD. METHODS: Review of previously done pharmacokinetic studies performed by the manufacturer of tiotropium. Data obtained through peer-reviewed publications and regulatory websites. RESULTS/CONCLUSIONS: The long duration of action with tiotropium is owing to prolonged, competitive binding to M(3) muscarinic receptors. Tiotropium is poorly absorbed following inhalation, which largely limits side effects. Metabolism of absorbed drug is minimal and excretion is largely through the kidneys. Tiotropium is efficacious and well tolerated by patients with COPD.

KW - administration, inhalation

KW - animals

KW - bronchodilator agents

KW - humans

KW - protein binding

KW - pulmonary disease, chronic obstructive

KW - receptors, muscarinic

KW - scopolamine derivatives

U2 - 10.1517/17425250902828337

DO - 10.1517/17425250902828337

M3 - Article

VL - 5

SP - 417

EP - 424

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 4

ER -